New Treatments in Chronic Liver Disease

March 26-27, 2011
Hyatt Regency La Jolla at Aventine
San Diego, California

More than 40 national CME conferences, in over 15 specialty areas
Scripps Conference Services & CME • www.scripps.org/conferenceservices
The William S. Haubrich Distinguished Lecturer

Albert Czaja, MD, FACC, AGAF, FACP

Albert J. Czaja, MD is emeritus professor of medicine at the Mayo Clinic College of Medicine, Rochester, Minnesota. He graduated from Dartmouth College in 1965, and Harvard Medical School in 1968. He was trained in internal medicine at the Philadelphia General Hospital, University of Pennsylvania Division, from 1968-1972. As a major in the United States Army Medical Corps from 1972-1975, Dr. Czaja was stationed at the United States Army Institute of Surgical Research at Fort Sam Houston in San Antonio, Texas. It was here that he performed key studies on the prevalence, patho-physiology and treatment of burn-related (Curling’s) gastric and duodenal ulcers. Dr. Czaja was an NIH Research Fellow in hepatology at the Mayo Clinic under the mentorship of W.H.J. Summerskill, MD from 1975-1977, and he joined the staff of the Mayo Clinic Division of Gastroenterology and Hepatology in 1977 where he was appointed professor of medicine in 1986.

His research has focused on chronic hepatitis, especially autoimmune hepatitis. Dr. Czaja received the AGA Mentor Award for distinguished clinical investigation in hepatology in 1997, the Henry S. Plummer Distinguished Physician Award by the Mayo Clinic Department of Medicine in 2006, the Distinguished Clinician Award of the AGA in 2007, and the Distinguished Clinician Educator Award (1st recipient) of the AASLD in 2008. Dr. Czaja was a founding member of the International Autoimmune Hepatitis Group in 1992.

William S. Haubrich, MD

Dr. William S. Haubrich graduated from Franklin & Marshall College in Lancaster, Pennsylvania in 1943 and from the medical school of Case-Western Reserve University in Cleveland, Ohio in 1947. His postgraduate training in pathology and internal medicine was at the United States Army Institute of Surgical Research at Fort Sam Houston in San Antonio, Texas. It was here that he performed key studies on the prevalence, patho-physiology and treatment of burn-related (Curling’s) gastric and duodenal ulcers. Dr. Czaja was an NIH Research Fellow in hepatology at the Mayo Clinic under the mentorship of W.H.J. Summerskill, MD from 1975-1977, and he joined the staff of the Mayo Clinic Division of Gastroenterology and Hepatology in 1977 where he was appointed professor of medicine in 1986.

His research has focused on chronic hepatitis, especially autoimmune hepatitis. Dr. Czaja received the AGA Mentor Award for distinguished clinical investigation in hepatology in 1997, the Henry S. Plummer Distinguished Physician Award by the Mayo Clinic Department of Medicine in 2006, the Distinguished Clinician Award of the AGA in 2007, and the Distinguished Clinician Educator Award (1st recipient) of the AASLD in 2008. Dr. Czaja was a founding member of the International Autoimmune Hepatitis Group in 1992.

Conference Location

Hyatt Regency La Jolla at Aventine

3777 La Jolla Village Drive
San Diego, CA 92122
Reservations: 800-233-1234  Hotel Direct: 858-552-1234
Web: hyattregencylajolla.com

Dining

Either located within the hotel or directly across from the front entrance, the Hyatt Regency La Jolla at Aventine offers many dining options:
- Barcino Grill – California cuisine
- Cafe Japengo – Sushi/Pacific Rim cuisine
- Fleming’s Prime Steakhouse
- Michael’s Lounge
- The Melting Pot – Fondue
- Truluck’s – Seafood, Steak & Crab House

Rates & Reservations

Please make your own reservations and mention the Scripps Liver Disease Conference to receive the reduced rate of $175 per night (excludes tax). Make your reservations early! A block of rooms will be held for Scripps until March 11, 2011. After this date, reservations will be accepted on a space and rate available basis only.

All Scripps discounted rooms come with:
- Complimentary wired internet in guest rooms
- Discounted self-parking
Course Overview

This CME conference will review new medications and therapies that are available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, autoimmune hepatitis, primary biliary cirrhosis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

There will be a fundamental change in treatment of chronic renal hepatitis C in 2011 with the addition of direct-acting antiviral (DAAs) drugs to current standard of care. There will be two separate lectures devoted to this topic this year. The first will be on triple therapies which will be approved in 2011. The second will be on combination therapies using two or more DAA’s.

We anticipate that there will be a number of demands placed on treatment providers which will be new, including different pretreatment predictors, viral resistance monitoring, rash and anemia management, and learning different therapeutic regimens. Looking beyond 2011, we see numerous combinations of DAA’s in development including protease inhibitors, nucleoside polymerase inhibitors, non-nucleoside polymerase inhibitors and NS5A inhibitors. All of these agents are entering phase 3 development rapidly. In hepatitis B, the treatments have not changed but there are more mature data available on viral resistance, long-term HBsAg loss and clinical outcomes. The explosive growth of NASH in the US has created a significant need for effective drug therapy. New therapies for NAFLD and NASH are in development and will be explored. The diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the few cancers with a growing incidence in the US. New oral therapy is moving this field forward. There will be an update on non-malignant hepatic tumors and their management as these are commonly seen in practice.

Educational Objectives

After participating in this course, attendees should be able to:

• Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the conditions.
• Integrate the algorithm for a therapeutic approach to treatment of HBV using new drugs.
• Discuss novel therapies for HCV including NSSA, protease and polymerase inhibitors.
• Update the skills and management required for transplant hepatology.
• Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
• Discuss new treatment paradigms for HCV direct-acting antiviral drugs.
• Recognizing the impact of NAFLD and NASH in the US and consider new treatment options for these patients.
• Describe the diagnosis and treatment of autoimmune hepatitis.
• Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder.
• Discuss the issues complicating drug treatment in decompensated hepatic C, hepatic encephalopathy and acute alcoholic hepatitis.
• Review the management of non-malignant hepatic tumors.

Accreditation & Disclosure

Accreditation

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum number of 9.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Documentation of awarded credit is provided for registered attendees in exchange for completed activity evaluation. Certificates of attendance are available, upon request, at the end of the course.

Nurses: The California State Board of Registered Nurses (BRN) accepts AMA PRA Category 1 Credit(s)™ as meeting continuing education requirements for license renewal. Most state Boards of Registered Nurses accept AMA PRA Category 1 Credit(s)™ as meeting continuing education requirements for license renewal. Nurses should check with their state board regarding use of CME credit.

Nurse Practitioners: This program will be submitted to the American Academy of Nurse Practitioners for continuing education credit.

Educational Grants

This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. At the time of printing, a complete listing of commercial supporters was not available. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.

Physicians Assistants: The American Academy of Physician Assistants accepts Category 1 credit from AMA Category 1 CME organizations accredited by ACCME.

Pharmacists: This conference meets CE Standards for Pharmacists by the California State Board of Pharmacy.

Cultural and Linguistic Competency

This activity is in compliance with California Assembly Bill 1195 which requires that all CME activities comprising a patient care element include curriculum addressing the topic of cultural and linguistic competency. The intent of this bill is to ensure that health care professionals are able to meet the cultural and linguistic concerns of a diverse patient population through effective and appropriate professional development. Cultural and linguistic competency was incorporated into the planning of this activity.
SATURDAY, MARCH 26, 2011

7:30 a.m.  Registration, Continental Breakfast & View Exhibits

8:30 a.m.  Welcome & Introduction
            Paul Pockros, MD

NAFLD, NASH, PBC, PSC and AIH
Moderator:  Paul Pockros, MD

8:40 a.m.  Advances in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
            Steve Harrison, MD

9:30 a.m.  What's New in Autoimmune hepatitis?
            Albert Czaja, MD

10:20 a.m.  Break & View Exhibits

Controversy
Corticosteroids or Pentoxyfyline for Acute Alcoholic Hepatitis?

10:40 a.m.  Corticosteroids
            Tarek Hassanein, MD

10:55 a.m.  Pentoxyfyline
            Steve Harrison, MD

11:10 a.m.  Panel Discussion

11:40 a.m.  Lunch

Hepatitis B and C
Moderator:  Donald Hillebrand, MD

12:40 p.m.  Triple Therapy for HCV in 2011
            Douglas Dieterich, MD

1:30 p.m.  Update on HBV
            Paul Martin, MD

2:20 p.m.  Changes in HCV Therapy for Difficult to Treat Patients and Beyond 2011
            Paul Pockros, MD

2:50 p.m.  Break & View Exhibits

Controversy
Treating Decompensated HCV Cirrhotic with Antiviral Therapy:  Yes or No?

3:20 p.m.  Pro
            Douglas Dieterich, MD

3:35 p.m.  Con
            Paul Martin, MD

4 p.m.  Panel Discussion

4:30 p.m.  Adjourn

SUNDAY, MARCH 27, 2011

7:30 a.m.  Continental Breakfast & View Exhibits

ESLD, HCC and Hepatic Fibrosis
Moderator:  Jill Lane, MD

8 a.m.  Diagnosis and Management of Hepatocellular Carcinoma in 2011
            Donald Hillebrand, MD

8:50 a.m.  Management of End Stage Liver Disease and Alcoholic Liver Disease
            Norman Sussman, MD

9:40 a.m.  Management of Non-Malignant Liver Tumors
            Randolph Schaffer, MD

10:30 a.m.  Break & View Exhibits

Controversy
Lactulose or Rifaximine as First Line Therapy for Hepatic Encephalopathy?

11 a.m.  Lactulose
            Norman Sussman, MD

11:15 a.m.  Rifaximine
            Donald Hillebrand, MD

11:30 a.m.  Panel Discussion

Noon  Adjourn
Conference Fees

Included: Course tuition, breakfasts, breaks, lunch and the course syllabus.
Not included: Travel costs, parking, lodging and dinners.

Full Conference

<table>
<thead>
<tr>
<th>Dates</th>
<th>Payment Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thru Feb 28</td>
<td>$245</td>
</tr>
<tr>
<td>Mar 1 – Mar 22</td>
<td>$275</td>
</tr>
<tr>
<td>Onsite after Mar 22</td>
<td>$300</td>
</tr>
</tbody>
</table>

Nurses/Nurse Practitioners

Allied Health Professionals

Physician Assistants/Pharmacists

Fellows and Residents

<table>
<thead>
<tr>
<th>Payment Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>$175</td>
</tr>
<tr>
<td>$200</td>
</tr>
<tr>
<td>$225</td>
</tr>
<tr>
<td>$105</td>
</tr>
<tr>
<td>$130</td>
</tr>
<tr>
<td>$155</td>
</tr>
</tbody>
</table>

Please note: there are no day rates available for this conference.

Conference Course Materials

Provided for all registered guests, but additional copies are available for purchase and will be mailed 2-4 weeks after the conference.

Printed Presentation Syllabus Only $75

Please Print Clearly

Should we have any conference communications or updates please provide your direct contact information.

FIRST NAME, MD, DO, PHD, RN, ETC.

BADGE NAME IF DIFFERENT FROM ABOVE

AFFILIATION/HOSPITAL/COMPANY

DIRECT MAILING ADDRESS

CITY / STATE / ZIP

DIRECT TELEPHONE

EMAIL

ASSISTANT NAME

ASSISTANT TELEPHONE

ASSISTANT EMAIL

PLEASE INDICATE ANY SPECIAL NEEDS INCLUDING DIETARY RESTRICTIONS.

Office use only:

DATE RECEIVED

CHECK NO / APPROVAL CD

AMOUNT

CONFIRMATION SENT

INITIALS

Payment Method

If paying by check, please make check payable to Scripps (in US dollars only).

If paying by credit card, please complete the information below.

VISA

MASTERCARD

AMEX

DISCOVER

CREDIT CARD NUMBER

EXPIRATION DATE

NAME ON CARD

SIGNATURE

BILLING ADDRESS IF DIFFERENT FROM ABOVE

Registration Confirmation

A confirmation letter will be e-mailed or mailed to you upon receipt of the conference registration form and payment. If you have not received it within two weeks, please contact the Scripps Conference Services & CME office.

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a $50 processing fee ($25 for Fellows and Residents), if your cancellation is received in writing no later than March 18, 2011. Attendee substitutions are allowed, but notification must be in writing by March 18, 2011. After this date, under no circumstances will refunds, credits, or substitutions be granted. No refunds or credits will be given to “no shows.”

Guest Attendance Policy

All conference activities (including educational sessions, meal functions, exhibit hall, etc.) are exclusively reserved for conference attendees. Non-registered guests (including children, family members, colleagues, etc.) are not allowed in the conference areas. Badges provided at registration are required for entrance into all functions and will be strictly enforced.

Scripps Conference Modification or Cancellation

Scripps reserves the right to modify the course’s schedule or program as necessary. Scripps also reserves the right to cancel this conference, in which case a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of Scripps cancellation.

Recording and Photography Clause

Scripps reserves exclusive rights to record (audio and video) and/or photograph all conference proceedings for use in marketing materials, presentations and course content sales.

Exhibit and Support Opportunities

For information on exhibit and support opportunities during this and many other Scripps educational conferences, please contact:

Scripps Conference Services & CME
858-652-5400
med.edu@scrippsshealth.org
26TH ANNUAL CONFERENCE

New Treatments in Chronic Liver Disease

March 26-27, 2011
Hyatt Regency La Jolla at Aventine
San Diego, California

Target Audience

- Hepatologists
- Gastroenterologists
- Infectious Disease Specialists
- Nurse Practitioners
- Physician Assistants
- Nurses
- Residents/Fellows and others desiring an update in these specialty areas

2011 CONFERENCE HIGHLIGHTS

- Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills.
- Controversies presented on the treatment of Decompensated HCV, Acute Alcoholic Hepatitis and Hepatic Encephalopathy.
- Audience Response System incorporated for instant feedback and interactive learning.
- Endorsed by the American College of Gastroenterology
- Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course.

Endorsed By

ACG